Palisade Bio, Inc. financial data

Symbol
PALI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
7750 El Camino Real, Suite 5200, Carlsbad, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Seneca Biopharma, Inc. (to 4/26/2021), Neuralstem, Inc. (to 1/23/2020)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 440 % -34.7%
Debt-to-equity 28.9 % +58.1%
Return On Equity -148 % -59.4%
Return On Assets -115 % -46.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.33M shares -85.6%
Common Stock, Shares, Outstanding 1.2M shares -87%
Entity Public Float 11.6M USD +43.2%
Common Stock, Value, Issued 11K USD -88%
Weighted Average Number of Shares Outstanding, Basic 1.5M shares +206%
Weighted Average Number of Shares Outstanding, Diluted 1.5M shares +206%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 16M USD
General and Administrative Expense 6.06M USD -1.51%
Operating Income (Loss) -14.6M USD -6.3%
Nonoperating Income (Expense) 566K USD -20.8%
Net Income (Loss) Attributable to Parent -14.1M USD -7.79%
Earnings Per Share, Basic 11.4 USD/shares +68.6%
Earnings Per Share, Diluted 11.4 USD/shares +68.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.04M USD -47.5%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD
Assets, Current 8.87M USD -45.5%
Property, Plant and Equipment, Net 3K USD -70%
Operating Lease, Right-of-Use Asset 113K USD -49.6%
Other Assets, Noncurrent 324K USD -26%
Assets 9.34M USD -45.3%
Accounts Payable, Current 366K USD -61.5%
Employee-related Liabilities, Current 449K USD -15.1%
Accrued Liabilities, Current 1.51M USD +90.1%
Liabilities, Current 2.68M USD +1.21%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 2.73M USD -8.61%
Retained Earnings (Accumulated Deficit) 133M USD +11.9%
Stockholders' Equity Attributable to Parent 6.61M USD -53.1%
Liabilities and Equity 9.34M USD -45.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.18M USD +9.81%
Net Cash Provided by (Used in) Financing Activities 2.02M USD -54.4%
Common Stock, Shares Authorized 280M shares 0%
Common Stock, Shares, Issued 1.2M shares -87%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.16M USD -226%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2K USD
Deferred Tax Assets, Valuation Allowance 29M USD +8.54%
Deferred Tax Assets, Gross 29.1M USD +8.17%
Operating Lease, Liability 122K USD -49%
Depreciation 1K USD 0%
Lessee, Operating Lease, Liability, to be Paid 128K USD -51.3%
Operating Lease, Liability, Current 122K USD +4.27%
Lessee, Operating Lease, Liability, to be Paid, Year Two 93K USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 94K USD -30.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6K USD -75%
Lessee, Operating Lease, Liability, to be Paid, Year Three 93K USD
Deferred Tax Assets, Operating Loss Carryforwards 24.7M USD +8.92%
Additional Paid in Capital 139M USD +5.04%
Share-based Payment Arrangement, Expense 740K USD +43.7%
Interest Expense 13K USD -7.14%